Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.58 |
| ▸ | PNMT | P11086 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14731704 | 0.84 | PNMT (0.67) | SIGMAR1TMEM97PNMTTAAR1KCNH2 | |
| SCHEMBL10859086 | 0.84 | PNMT (0.67) | SIGMAR1TMEM97PNMTTAAR1KCNH2 | |
| SCHEMBL25823578 | 0.84 | TMEM97 (0.44) | SIGMAR1TMEM97PNMTTAAR1KCNH2 | |
| SCHEMBL25823349 | 0.82 | TMEM97 (0.43) | SIGMAR1TMEM97PNMTTAAR1KCNH2 | |
| SCHEMBL18996666 | 0.82 | TMEM97 (0.43) | SIGMAR1TMEM97PNMTTAAR1KCNH2 | |
| Hydrochloric Acid SCHEMBL14829092 | 0.82 | PNMT (0.65) | SIGMAR1TMEM97PNMTTAAR1KCNH2 | |
| Hydrochloric Acid SCHEMBL14829137 | 0.82 | PNMT (0.65) | SIGMAR1TMEM97PNMTTAAR1KCNH2 | |
| SCHEMBL4716937 | 0.81 | TMEM97 (0.57) | SIGMAR1TMEM97PNMTTAAR1KCNH2 | |
| SCHEMBL4910377 | 0.81 | PNMT (0.58) | SIGMAR1TMEM97PNMTTAAR1KCNH2 | |
| SCHEMBL8294098 | 0.80 | SIGMAR1 (0.52) | SIGMAR1TMEM97KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2021074898-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-04-22 | — | — | WO | disclosed |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-12 | — | — | US | disclosed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180185306-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-07-05 | — | — | US | disclosed |
| US-9902754-B2 | Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction | UNIVERSITY OF COPENHAGEN (DK) | 2018-02-27 | — | — | US | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
| US-20160176924-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | UNIVERSITY OF COPENHAGEN (DK) | 2016-06-23 | — | — | US | disclosed |
| US-9241967-B2 | Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction | UNIVERSITY OF COPENHAGEN (DK) | 2016-01-26 | — | — | US | disclosed |
| US-20110178022-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | UNIVERSITY OF COPENHAGEN (DK) | 2011-07-21 | — | — | US | disclosed |
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | BRDT, AADAC, ACIN1 | SIGMAR1 4283/4885TMEM97 3627/4885PNMT 842/4885 |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | SIGMAR1 1097/4885TMEM97 523/4885PNMT 783/4885 |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | CYP2A6, CYP2B6, CYP4A11 | SIGMAR1 1833/4885TMEM97 3475/4885PNMT 3085/4885 |
| US-20160176924-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | PSD, GRIN1, GRIN3B | SIGMAR1 1076/4885TMEM97 311/4885PNMT 284/4885 |
| US-20110178022-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | GRIN1, PSD, GRIN3B | SIGMAR1 1023/4885TMEM97 316/4885PNMT 277/4885 |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | CYP2A6, CYP2B6, CYP4A11 | SIGMAR1 1833/4885TMEM97 3475/4885PNMT 3085/4885 |
| US-20180185306-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | PROC, GLS, NLN | SIGMAR1 4860/4885TMEM97 4714/4885PNMT 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.